Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a KRAS-Targeted Combination Therapy in Metastatic Pancreatic Adenocarcinoma
The annual report required under 21 C.F.R. 312.33 is a short document with a long list of contributors: clinical operations, pharmacovigilance, nonclinical development, chemistry, manufacturing, and controls, quality, and regulatory publishing all supply content that must reconcile to the same data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND in which an oral KRAS-pathway inhibitor is combined with a standard multi-agent chemotherapy backbone as first-line treatment of metastatic pancreatic adenocarcinoma. It sets out the reporting period and deadline, study accounting (56 of 80 planned participants entered), the content required by each paragraph of the regulation, placement of every component in Module 1.13 of the eCTD, Form FDA 1571 entries, a draft cover letter, and an 11-step timeline. It corrects a common error, placement of the report in Module 1.3, and closes with recommendations for regulatory operations teams.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Authors
- Avinash Dundigalla
- Peivand Pirouzi
- Afeefa Mahmood
- Kritica
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24373167
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00